Objective: To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD).

One such investigative compound currently in clinical trials is an amino acid, N-Acetyl Cysteine (NAC), which appears to reduce the core symptoms of bipolar disorder, schizophrenia, depression ...

I have schizoaffective disorder, bipolar type — a combination of schizophrenia and bipolar disorder — and I agree that this is a monumental development for my community. Historically ...

Researchers Discover a Mechanism That Impairs Synaptic Plasticity in the Brains of Schizophrenia Patients Sep. 4, 2024 — A study mapped genes linked to schizophrenia and uncovered a mechanism ...

For those who live with schizophrenia, the sound of voices — voices that no one else can hear — can be an overwhelming and ...

About one in 300 people worldwide are affected by schizophrenia, but for decades treatment options have been both static and limited. If the FDA approves the twice-daily pill on Thursday ...

At 30, John Nash suffered his first bout of full-blown schizophrenia, a disease sometimes called the "cancer of the mind." Aolicai Nash, his wife, was 26 at the time. "I wanted to help him," she ...

Caplyta (lumateperone) was approved for the treatment of schizophrenia in 2019 and for depressive episodes linked to bipolar I or bipolar II disorder (bipolar depression) in 2021. Caplyta can be ...

The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in ...

The National Institute of Mental Health defines schizophrenia as a "severe and disabling" condition characterized by "hallucinations, delusions, and thought disorder." Around 2.8 million American ...

Hi. I'm Michele Hammer and I have schizophrenia. Schizophrenia is a mental illness that changes the way you think, feel, and act. It's broken down into three separate categories, positive ...